NCT00410553 is a Phase 1 clinical trial of Eribulin Mesylate in Adult Solid Neoplasm, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT00410553?

NCT00410553 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT00410553?

Interventions in NCT00410553: Eribulin Mesylate, Gemcitabine Hydrochloride.

What condition does NCT00410553 study?

NCT00410553 studies Adult Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7.

Is NCT00410553 still recruiting?

NCT00410553 is currently completed. Last updated 3 October 2018.

Last reviewed 2018-10-03 · How we verify

NCT00410553

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery

Completed Phase 1 Last updated 3 October 2018

What this trial tests

Phase 1 trial testing Eribulin Mesylate in Adult Solid Neoplasm in 45 participants. Completed in 24 October 2012.

Timeline

14 November 2006

Primary endpoint
24 October 2012

24 October 2012

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	14 November 2006
Primary completion	24 October 2012
Estimated completion	24 October 2012
Sites	2 locations across Canada

Drugs / interventions tested

Eribulin Mesylate — full drug profile →
Gemcitabine Hydrochloride — full drug profile →

Conditions studied

Adult Solid Neoplasm — all drugs for Adult Solid Neoplasm →
Recurrent Ovarian Carcinoma — all drugs for Recurrent Ovarian Carcinoma →
Recurrent Uterine Corpus Carcinoma — all drugs for Recurrent Uterine Corpus Carcinoma →
Stage III Ovarian Cancer AJCC v6 and v7 — all drugs for Stage III Ovarian Cancer AJCC v6 and v7 →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with Adult Solid Neoplasm or Recurrent Ovarian Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial is studying the side effects and best dose of eribulin mesylate and gemcitabine hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as eribulin mesylate and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Marine Sponge Natural Products with Anticancer Potential: An Updated Review.
Calcabrini C, Catanzaro E, Bishayee A, Turrini E, et al · · 2017 · cited 91× · PMID 29027954 · DOI 10.3390/md15100310
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.
Ayoub JP, Verma Sh, Verma S. · · 2012 · cited 14× · PMID 22514495 · DOI 10.3747/co.19.1024
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Lheureux S, Oza AM, Laurie SA, Halford R, et al · · 2015 · cited 8× · PMID 26554651 · DOI 10.1038/bjc.2015.343

Verify or expand the search:

Other trials of Eribulin Mesylate

Trials testing the same drug.

NCT06590558 — Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Er · Phase 1 · withdrawn
NCT05041101 — Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer · Phase 1, PHASE2 · terminated
NCT04579224 — Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothel · Phase 3 · active not recruiting
NCT04345913 — Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer · Phase 1, PHASE2 · active not recruiting
NCT05206656 — Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer · Phase 2 · completed

Other recruiting trials for Adult Solid Neoplasm

Currently open trials in the same condition.

NCT02432963 — Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy · Phase 1 · active not recruiting
NCT01375829 — Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · Phase 1 · active not recruiting
NCT01281176 — High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid · Phase 1 · active not recruiting
NCT00878163 — GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Panc · Phase 1 · active not recruiting
NCT00045201 — Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors · Phase 1 · active not recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00410553 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 3 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00410553.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing